Have a feature idea you'd love to see implemented?
Let us know!
NRBO NeuroBo Pharmaceuticals Inc
Price (delayed)
$2.8
Market cap
$23.69M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.91
Enterprise value
-$4.08M
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of 4 drug candidates. The
Highlights
The debt fell by 9% QoQ
The equity has surged by 88% since the previous quarter but it has declined by 25% year-on-year
The quick ratio has dropped by 60% year-on-year but it rose by 23% since the previous quarter
The EPS has shrunk by 143% YoY and by 53% QoQ
The company's net income has shrunk by 133% YoY and by 56% QoQ
Key stats
What are the main financial stats of NRBO
Market
Valuations
Earnings
Shares outstanding
8.46M
Market cap
$23.69M
Enterprise value
-$4.08M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.73
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$25.9M
EBITDA
-$25.88M
Free cash flow
-$19.95M
Per share
Balance sheet
Liquidity
EPS
-$4.91
Free cash flow per share
-$3.68
Book value per share
$3.86
Revenue per share
$0
TBVPS
$5.3
Total assets
$28.75M
Total liabilities
$9.81M
Debt
$170,000
Equity
$18.94M
Working capital
$18.81M
Debt to equity
0.01
Current ratio
2.94
Quick ratio
2.88
Net debt/EBITDA
1.07
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-109.1%
Return on equity
-154%
Return on invested capital
N/A
Return on capital employed
-136%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NRBO stock price
How has the NeuroBo Pharmaceuticals stock price performed over time
Intraday
-1.06%
1 week
-11.39%
1 month
-12.5%
1 year
-18.6%
YTD
-24.32%
QTD
-11.67%
Financial performance
How have NeuroBo Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$26.53M
Net income
-$25.9M
Gross margin
N/A
Net margin
N/A
The company's net income has shrunk by 133% YoY and by 56% QoQ
NRBO's operating income is down by 34% YoY and by 31% from the previous quarter
Growth
What is NeuroBo Pharmaceuticals's growth rate over time
Valuation
What is NeuroBo Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.73
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has shrunk by 143% YoY and by 53% QoQ
The equity has surged by 88% since the previous quarter but it has declined by 25% year-on-year
The P/B is 86% below the 5-year quarterly average of 5.4 and 44% below the last 4 quarters average of 1.3
Efficiency
How efficient is NeuroBo Pharmaceuticals business performance
The ROE has shrunk by 154% YoY and by 71% QoQ
The ROA has plunged by 150% YoY and by 57% from the previous quarter
Dividends
What is NRBO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NRBO.
Financial health
How did NeuroBo Pharmaceuticals financials performed over time
NeuroBo Pharmaceuticals's total assets is 193% higher than its total liabilities
The total liabilities has surged by 146% year-on-year and by 41% since the previous quarter
NeuroBo Pharmaceuticals's total assets has surged by 69% QoQ
The debt is 99% lower than the equity
The equity has surged by 88% since the previous quarter but it has declined by 25% year-on-year
NRBO's debt to equity has dropped by 50% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.